Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E16.83 EPS (ttm)17.13 Insider Own0.10% Shs Outstand219.10M Perf Week9.89%
Market Cap63.18B Forward P/E13.85 EPS next Y20.82 Insider Trans-3.96% Shs Float218.43M Perf Month28.38%
Income3.82B PEG1.87 EPS next Q5.02 Inst Own88.70% Short Float1.14% Perf Quarter2.96%
Sales11.24B P/S5.62 EPS this Y24.00% Inst Trans0.13% Short Ratio1.32 Perf Half Y5.52%
Book/sh52.05 P/B5.54 EPS next Y5.12% ROA18.50% Target Price332.50 Perf Year-9.87%
Cash/sh- P/C- EPS next 5Y9.01% ROE36.60% 52W Range223.02 - 338.51 Perf YTD-5.88%
Dividend- P/FCF- EPS past 5Y31.30% ROI23.50% 52W High-15.20% Beta0.92
Dividend %- Quick Ratio2.60 Sales past 5Y17.90% Gross Margin88.20% 52W Low28.71% ATR6.25
Employees7350 Current Ratio3.00 Sales Q/Q11.70% Oper. Margin47.90% RSI (14)69.30 Volatility2.18% 2.09%
OptionableYes Debt/Eq0.00 EPS Q/Q21.60% Profit Margin34.00% Rel Volume0.86 Prev Close288.35
ShortableYes LT Debt/Eq0.57 EarningsJul 21 BMO Payout0.00% Avg Volume1.89M Price287.04
Recom2.10 SMA2010.38% SMA5011.13% SMA2006.07% Volume232,907 Change-0.45%
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Jul-28-16 09:30AM  The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
09:05AM  What Will Be a Key Driver of Biogens Future Valuations?
08:02AM  Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Jul-27-16 03:25PM  Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
02:07PM  5 Undervalued Growth Stocks to Buy Today at Motley Fool
11:06AM  Biogen Misses EndPoints in Synergy Trial for Opicinumab
09:09AM  BIIB Continues to Lead the MS Treatment Market in the US in 2016
08:00AM  TauRx Alzheimer's drug fails in large study; some benefit seen Reuters
08:00AM  Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure
07:50AM  Major Biotechs See Increased Short Interest Bets at 24/7 Wall St.
Jul-26-16 11:57AM  A lesser-known multiple-sclerosis issue money problems at MarketWatch
11:10AM  Tecfidera Is Still a Key Growth Driver for Biogen in 2016
09:08AM  Whats Boosted Investors Confidence in Biogen in 2016?
08:21AM  An Investing Overview of the Multiple Sclerosis Market at Motley Fool
Jul-25-16 04:59PM  What Are Analysts Recommendations for Biogen in 2016?
04:59PM  How Do Biogens Valuation Multiples Compare with Its Peers?
02:23PM  Fresh Research Reports For Intel (INTC), AT&T (T) & Others
09:30AM  Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
Jul-22-16 06:04PM  Pharma Industry Outlook: Fundamentals Remain Strong
02:57PM  ETFs with exposure to Biogen, Inc. : July 22, 2016
01:15PM  What Role Did Innovative Medicines Play in Novartiss 2Q16 Earnings?
12:24PM  Biogen (BIIB) Stock Up on CEO Transition, Fueling Sale Speculation
12:13PM  Six Major Biotech Acquisitions You Could See in 2016 (Part 2) at Forbes
11:40AM  Biogen: Prelude to a Sale? at Barrons.com
11:40AM  Biogen Should Either a Buyer or a Seller Be
11:33AM  Biogen Inc: How Double-Digit Growth Got Trumped at Motley Fool
10:00AM  Biogen Trounces Q2 Estimates; CEO to Retire Soon at Investopedia
09:15AM  Post Earnings Coverage as Biogen Post 23% growth in EPS Accesswire
08:57AM  Post Earnings Coverage as Biogen Post 23 Percent growth in EPS
12:56AM  [$$] Biogen Announces CEO Search, Lifts Guidance at The Wall Street Journal
12:53AM  [$$] No Miracle Cures for Biogen at The Wall Street Journal
Jul-21-16 06:03PM  Stocks Lose Steam; Breakouts From eBay, Domino's +7.64%
06:00PM  Stocks Slide Into the Red Thursday
05:00PM  Biogen CEO Quits Amid M&A Speculation; Company Hikes Outlook
04:13PM  [$$] Biogen Announces CEO Search, Lifts Guidance at The Wall Street Journal
03:33PM  Biogen CEO has 'mixed emotions' as he leaves company after 6 years at CNBC
03:20PM  Biogen CEO George Scangos to step down, search for successor to begin at bizjournals.com
02:55PM  Exit of Biogen CEO George Scangos could be big for Bay Area biotechs at bizjournals.com
02:49PM  Edited Transcript of BIIB earnings conference call or presentation 21-Jul-16 12:30pm GMT
02:08PM  Rallying biotech looks interesting for value investors, says top-rated analyst at CNBC
01:24PM  Biogen's New CEO Needs a New Plan at Bloomberg
01:17PM  Dow Leads Stocks Lower; Biogen Fuels Biotech Rebound
01:10PM  Evercore's Schoenebaum Explains Biotech Boom on CNBC
01:04PM  [$$] No Miracle Cures for Biogen at The Wall Street Journal
01:00PM  Biogen: Earnings Beat Expectations, Maintaining Current Fair Value Estimate at Morningstar
12:40PM  Stocks Slip into the Red Midday Thursday
12:09PM  Stocks Extend Declines as Southwest Pressures Airlines
12:00PM  Is biotech back?
11:22AM  Biogen rises after 2nd-quarter results surpass forecasts
11:19AM  Biogen Shares Climb on Earnings Beat, CEO Departure at TheStreet
10:12AM  Mattel Jumps On Barbie Sales Surge, Plus 4 Other Trending Stocks at Insider Monkey
10:07AM  Q2 Earnings Central Stays Busy, GM Sets New Record
10:02AM  Biogen: CEO Departing; Is This Drug Maker In Play? at Barrons.com
09:55AM  Biogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook
09:14AM  Biogen (BIIB) Stock Soars on Q2 Earnings, Revenue Beat
08:47AM  Morning Movers: Biogen, General Motors Jump on Earnings; Tesla Falls at Barrons.com
08:37AM  Biogen (BIIB) Beats on Q2 Earnings by a Huge Margin
08:36AM  Biogen's Q2 Numbers, Outlook Exceed Street Expectations
08:11AM  Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership
07:12AM  Biogen's stock jumps after results beat expectations; CEO to leave at MarketWatch
07:12AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Biogens CEO Is Out After Management Changes, Sales Struggles at Bloomberg
07:07AM  Q2 2016 Biogen Inc Earnings Release - Before Market Open
07:00AM  Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion Business Wire
Jul-20-16 03:36PM  Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
02:51PM  Biogen: This is Getting Annoying at Barrons.com
11:54AM  How this biotech analyst thinks the presidential election will impact the overall health care space
09:47AM  Biotech: As Cheap as They Come at Barrons.com
Jul-19-16 10:06AM  Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF
Jul-18-16 03:05PM  Biogens Hemophilia Drugs Could See Strong Revenue Growth
12:07PM  Biogen: Key Analyst Recommendations in 2016
08:14AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : July 18, 2016
07:30AM  Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress Business Wire
Jul-17-16 09:05PM  SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency Business Wire
09:00PM  Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency Business Wire
05:06PM  3 Big-Cap Drugmakers Reporting Earnings This Week
Jul-16-16 09:03AM  4 Rock-Solid, Cheap Biotech Stocks at Motley Fool
Jul-15-16 04:55PM  Here's Why Action Alerts PLUS Exited Biogen Today
04:19PM  Biotech: Steak, But No Sizzle at Barrons.com
03:51PM  Why Biogens Upping Its Focus on Multiple Sclerosis in 2016
03:51PM  Will Biogen Report Strong 2Q16 Revenue Growth?
02:48PM  Street Talk: CBS, QCOM, CMG & more
02:43PM  What Biogen Wants in a New CIO at The Wall Street Journal
09:17AM  Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?
08:19AM  Does Biogen's Lower P/E Ratio Make It a Better Buy Than Celgene? at Motley Fool
Jul-14-16 04:42PM  Drug Companies Really Dont Care About the Price Hike Backlash at Fortune
03:55PM  Better Days Ahead for Biotech at Barrons.com
10:42AM  How Much Do Stock Prices Matter in Biotech? at Motley Fool
04:48AM  [$$] Biosimilars set topple two of the world's biggest drug franchises at Financial Times
Jul-13-16 05:08PM  WhiteWave Rides Another Downgrade
08:10AM  Short Sellers Become More Selective on Major Biotechs at 24/7 Wall St.
12:01AM  The GOP Needs To Tackle The High Price Of Prescription Drugs at Forbes
Jul-12-16 12:21PM  Which Pipeline Has Better Potential: Celgene or Biogen? at Motley Fool
10:37AM  5 Stocks With Rising RSIs That Lost Hedge Fund Support at Insider Monkey
Jul-11-16 05:11AM  Four high-quality biotech companies trading like risky startups at MarketWatch
Jul-09-16 02:03PM  How Marijuana Could Play a Role in Alzheimer's Disease Treatment at Motley Fool
Jul-08-16 07:43AM  Why Biogen Inc. Stock Dropped 15.7% in June at Motley Fool
Jul-07-16 04:40PM  Surprise: JNJ Just Did Celgene a Huge Favor
Jul-06-16 04:18PM  Strong Q2 For Biotech Forecast As Drug Prices Keep Going Up
04:10PM  Portfolio Roundup: AAPL, BIIB, COST
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM